|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
OncoSec Medical Inc.
| | | Phone: | (855) 662-6732 | Fax: | (855) 430-3832 | Year Established: | 2010 | Employees: | 11 | Ticker: | ONCS | Exchange: | OTCBB | Main Contact: | Daniel J. O'Connor, CEO | | Other Contacts: | Avtar Dhillon, M.D., Co-Founder & Chairman Punit Dhillon, Co-Founder & President Christopher G. Twitty, Ph.D., CSO Sara M. Bonstein, CFO & COO Robert W. Ashworth, Ph.D., VP, Regulatory Kellie Malloy Foerter, Chief Clinical Development
Officer
| | Company Description | OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulseŽ, for the treatment of cancer. ImmunoPulseŽ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulseŽIL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulseŽIL-12, is currently in clinical development for several indications, including metastatic melanoma, head and neck cancer, and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulseŽ IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulseŽ platform. | |
|
|
|
|
|